Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study

被引：0
|
作者：
Pradhan, Richeek [1 ]
Azoulay, Laurent [1 ]
Platt, Robert W. [2 ]
Yu, Oriana H. Y. [3 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[3] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
55
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors and the risk of acute liver injury among patients with type 2 diabetes
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana Hoi Yun
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 114 - 114
  • [22] Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study
    Hou, Wen-Hsuan
    Chang, Kai-Cheng
    Li, Chung-Yi
    Ou, Huang-Tz
    PAIN, 2016, 157 (09) : 1954 - 1959
  • [23] COMPARATIVE EFFECTIVENESS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS VERSUS SULFONYLUREAS IN ADDITION TO METFORMIN: A POPULATION-BASED COHORT STUDY OF PATIENTS WITH DIABETES
    Wu, Hon-Yen
    Wang, Jui
    Chien, Kuo-Liong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I896 - I897
  • [24] Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
    Hong, Sangmo
    Han, Kyungdo
    Park, Cheol-Young
    MAYO CLINIC PROCEEDINGS, 2020, 95 (01) : 101 - 112
  • [25] Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
    Seoyoung C. Kim
    Robert J. Glynn
    Jun Liu
    Brendan M. Everett
    Allison B. Goldfine
    Acta Diabetologica, 2014, 51 : 1015 - 1023
  • [26] Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study
    Bea, Sungho
    Son, Heejun
    Bae, Jae Hyun
    Cho, Sun Wook
    Shin, Ju-Young
    Cho, Young Min
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 108 - 117
  • [27] Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
    Kim, Seoyoung C.
    Glynn, Robert J.
    Liu, Jun
    Everett, Brendan M.
    Goldfine, Allison B.
    ACTA DIABETOLOGICA, 2014, 51 (06) : 1015 - 1023
  • [28] DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES
    Chen, W. S.
    Chang, Y. S.
    Tsai, C. Y.
    Chang, C. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1246 - 1247
  • [29] Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study
    Driessen, Johanna H. M.
    van den Bergh, Joop P. W.
    van Onzenoort, Hein A. W.
    Henry, Ronald M. A.
    Leufkens, Hubert G. M.
    de Vries, Frank
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 421 - 428
  • [30] Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study
    Seong, Jong-Mi
    Kim, Jong Joo
    Kim, Hae Jin
    Sohn, Hyun Soon
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
12345